SCHEMBL3665178

SCHEMBL3665178

Oc1c(I)c(I)nc2ccccc12

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DHODH Q02127 4/20 0.43
PDE10A Q9Y233 1/20 0.43
KDM4E B2RXH2 3/20 0.40
ALDH1A1 P00352 3/20 0.40
MAOA P21397 2/20 0.40
GLA P06280 2/20 0.40
HPGD P15428 2/20 0.40
CASP1 P29466 2/20 0.40
CASP7 P55210 2/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
HSD17B10 Q99714 2/20 0.40
CHRM2 P08172 1/20 0.40
ADRA2A P08913 1/20 0.40
ADORA3 P0DMS8 1/20 0.40
CHRM1 P11229 1/20 0.40
NQO2 P16083 1/20 0.40
DRD1 P21728 1/20 0.40
ACHE P22303 1/20 0.40
SLC6A2 P23975 1/20 0.40
ADRA1A P35348 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28489861 0.80 DHODH (0.41) DHODHPDE10AKDM4EALDH1A1MAOA
SCHEMBL12989093 0.80 GPR3 (0.53) DHODHPDE10AKDM4EALDH1A1HPGD
SCHEMBL667261 0.80 MAOA (0.52) DHODHPDE10AKDM4EALDH1A1MAOA
SCHEMBL10527277 0.80 MAOA (0.47) DHODHPDE10AKDM4EALDH1A1MAOA
Acridone SCHEMBL243819 0.77 KDM4E (0.56) DHODHPDE10AKDM4EALDH1A1MAOA
Acridone SCHEMBL5719993 0.75 KDM4E (0.54) DHODHPDE10AKDM4EALDH1A1MAOA
Acridone SCHEMBL10800711 0.75 KDM4E (0.54) DHODHPDE10AKDM4EALDH1A1MAOA
Acridone SCHEMBL345058 0.75 ALDH1A1 (0.54) DHODHPDE10AKDM4EALDH1A1MAOA
Acridone SCHEMBL429571 0.75 ALDH1A1 (0.54) DHODHPDE10AKDM4EALDH1A1MAOA
SCHEMBL10431561 0.74 DHODH (0.41) DHODHPDE10AKDM4EALDH1A1MAOA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3113843-B1 COMPOSITION AND METHOD FOR ENHANCING WOUND HEALING TUFFLEY MARK (AU) 2022-12-14 EP claimed
US-20180051412-A1 SPECIALTY FABRICS HAVING ANTI-MICROBIAL, STAIN RELEASE, AND DUST RESISTANT PROPERTIES RELIANCE INDUSTRIES LIMITED (IN) 2018-02-22 US claimed
US-4485091-A HYDROGEN PEROXIDE, OIL IN WATER EMULSION QUINODERM LIMITED (GB) 1984-11-27 US claimed
US-20250346910-A1 METHODS AND COMPOSITIONS TO PREVENT MICROBIAL INFECTION COMMENSE BIO INC (US) 2025-11-13 US disclosed
US-12163135-B2 Methods and compositions to prevent microbial infection BioPlx, Inc. (US) 2024-12-10 US disclosed
EP-4158010-A1 METHODS FOR STABLE GENOMIC INTEGRATION IN RECOMBINANT MICROORGANISMS BioPlx, Inc. (US) 2023-04-05 EP disclosed
EP-3113843-B1 COMPOSITION AND METHOD FOR ENHANCING WOUND HEALING TUFFLEY MARK (AU) 2022-12-14 EP disclosed
US-20220288135-A1 LIVE BIOTHERAPEUTIC COMPOSITIONS AND METHODS BioPlx, Inc. (US) 2022-09-15 US disclosed
US-20220025364-A1 METHODS FOR STABLE GENOMIC INTEGRATION IN RECOMBINANT MICROORGANISMS COMMENSE BIO, INC. 2022-01-27 US disclosed
US-11058649-B2 Composition and method for enhancing wound healing TUFFLEY MARK (AU) 2021-07-13 US disclosed
US-20190269630-A1 COMPOSITION AND METHOD FOR ENHANCING WOUND HEALING TUFFLEY MARK (AU) 2019-09-05 US disclosed
US-20180051412-A1 SPECIALTY FABRICS HAVING ANTI-MICROBIAL, STAIN RELEASE, AND DUST RESISTANT PROPERTIES RELIANCE INDUSTRIES LIMITED (IN) 2018-02-22 US disclosed
WO-2018004664-A1 WATER-BASED EMOLLIENT COMPOSITIONS AND METHODS OF USE THEREFOR TISSUE TOOLS LLC (US) 2018-01-04 WO disclosed
US-20170014358-A1 COMPOSITION AND METHOD FOR ENHANCING WOUND HEALING TUFFLEY MARK (AU) 2017-01-19 US disclosed
EP-3113843-A1 COMPOSITION AND METHOD FOR ENHANCING WOUND HEALING Tuffley, Mark (AU) 2017-01-11 EP disclosed
WO-2016072939-A1 FORMULATIONS COMPRISING ANTIMICROBIAL AGENTS WITH HYDROPHOBIC MOIETIES AND USES THEREOF NATIONAL UNIVERSITY OF SINGAPORE (SG) 2016-05-12 WO disclosed
WO-2015131220-A1 COMPOSITION AND METHOD FOR ENHANCING WOUND HEALING TUFFLEY MARK (AU) 2015-09-11 WO disclosed
EP-2222319-A2 TOPICAL DRUGS FOR USE IN ANTIFUNGAL THERAPY Bayer Consumer Care AG (CH) 2010-09-01 EP disclosed
WO-2009062746-A2 TOPICAL DRUGS FOR USE IN ANTIFUNGAL THERAPY BAYER CONSUMER CARE AG (CH) 2009-05-22 WO disclosed
US-4485091-A HYDROGEN PEROXIDE, OIL IN WATER EMULSION QUINODERM LIMITED (GB) 1984-11-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190269630-A1 COMPOSITION AND METHOD FOR ENHANCING WOUND HEALING CALCA, PROC, CYP24A1 DHODH 1121/4885PDE10A 1332/4885KDM4E 3991/4885
US-20170014358-A1 COMPOSITION AND METHOD FOR ENHANCING WOUND HEALING CALCA, PROC, CYP24A1 DHODH 1121/4885PDE10A 1332/4885KDM4E 3991/4885
US-11058649-B2 Composition and method for enhancing wound healing CALCA, PROC, CYP24A1 DHODH 1121/4885PDE10A 1332/4885KDM4E 3991/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.